Drug intelligence / Profile preview

Protears

Development stage: Unknown
Modality: Microbiome-Derived Products → Microbiome Therapeutics, Device-based Delivery → Drug Delivery Systems
Administration: Ophthalmic

Overview

Protears are ophthalmic eye drops approved in the European Union as a medical device for the treatment of dry eye disease. The product contains an ophthalmic bacterial lysate of Latilactobacillus sakei, which functions as a postbiotic. Clinical studies have demonstrated that Protears significantly reduce the signs and symptoms of dry eye disease by suppressing the inflammatory response on the ocular surface, specifically by decreasing tear levels of inflammatory cytokines such as IL-6, TNFα, and IFNγ.

Brand names: Protears

Targets

IL-6 (Interleukin 6)IFNG (Interferon gamma)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Protears.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protears.

Explore the full profile